Replies to post #694581 on NorthWest Biotherapeutics Inc (NWBO)

[saxxie2]

Thanks for this video!

youtu.be/UGH8f65NSpQ?si=wbN34mYOpjfD0DdY

Some patients in the DCVax-L trial survived over 20 years enjoying a good quality of life!

[CherryTree1]

Thanks Lykiri - very fun watching

[antihama]

When I saw the first basketball shot taken and it clunked off the rim, I was saying to myself "what, you put that in a video" but quickly realized w consecutive clunked shots the humor of it all since he was talking about RNA vaccines et al.

[Sir Pumpernickel]

The video really makes sense!!! WAY in the future when legacy shareholders are stiffs in the ground and it won’t be NWBO anyway!!!!!
Multiple, infinity, continuous, borrowing, and out of eye rolls zzzzzzzzz!!!!!!!
Pumpernickel……. YuYU…….LALAAAAA……. YuLAYuLAYuuuuuuuuuuuuuuuuuu……..AAAAAAAAAAAAAAAAAWWWWWHHHOOOOOOOOOoooooooeeeeeeeeee!!!!!!!!!!!!

[sentiment_stocks]

Interesting... but the video states that the paper cited the mOS of the GBM patients treated with both DCVax and Poly ICLC was 52.5 months, which is incorrect, I believe, as my numbers for those 5 patients (taken from the paper's supplement) indicated a mOS of 28.6 months.

From the list of 5 Poly ICLC + DCVax-L patients, each of their OS were as follows:
24.5
26.6
28.6 median
28.6
52.5

From my more detailed, older post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172833579&txt2find=poly%20iclc

While I certainly wish the median was 52.5, I believe the video is incorrect. 52.5 was instead the longest living patient of the five.
Interestingly, the longest living patient was the placebo patient (meaning, the patient ONLY received DCVax-L), and that patient lived 61.2 months in the trial.

That said, the placebo patient was methylated GBM, and those more fortunate patients, we already know (from the P3 trial), do very well with DCVax-L on its own. It's the unmethylated patients that especially should benefit when you throw Poly ICLC into their treatment mix, IMO.